1. The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

3. Introduction/Overview

4. T2DM as a Risk Factor for CVD

5. Prevalence Rates of CV Comorbidities in Persons With T2DM: Results of a Systematic Literature Review

6. Mechanisms Associating Type 2 Diabetes and Cardiovascular Disease

7. Shorter-, Longer-Acting GLP-1 RAs: Compositional Differences and Comparative Clinical Trial Data

8. Molecular Structure: GLP-1, Liraglutide, Dulaglutide, Albiglutide, Exenatide, Lixisenatide, and Semaglutide

9. Results From SUSTAIN 1-5 (Semaglutide): Change in HbA1c

10. SUSTAIN 7: Changes in HbA1c and Body Weight, Semaglutide vs Dulaglutide

11. ELIXA: Primary Outcome: CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for Unstable Angina

12. Primary Endpoint Results From the LEADER Trial*

13. HARMONY OUTCOMES Primary Endpoint Results: Time to CV Death, MI or Stroke (MACE)

14. SUSTAIN-6 (Semaglutide): Primary Outcome Results

15. Dulaglutide’s Effect on the CV Composite Primary Outcome: First Occurrence of Nonfatal MI, Nonfatal Stroke, CV Death

16. Difference in CVOT Design: Patient Populations (Inclusion Criteria and Baseline Characteristics

17. CVOT Trials: Differences in Cardiovascular Risk

18. REWIND Results: CV Composite in Prespecified Subgroups

19. GLP-1 RAs and Experimental Models of CVD

20. Patient Preferences: Injection vs Increased Urinary Frequency

21. Sodium Salcaprozate (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) Oral Absorption Promoter

22. PIONEER 1, 2, 3, 4, and 7: Change in HbA1c

23. PIONEER Clinical Development Program

24. PIONEER 1,5,8: Body Weight Change From Baseline: Oral Semaglutide vs Liraglutide

25. PIONEER 4: Estimated Mean Change From Baseline in HbA1c Oral Semaglutide vs SC Liraglutide

26. Will an Oral GLP-1 RA Change the Treatment Paradigm?

27. How Big a Problem Is Needle Phobia?

28. Pharmacologic Therapy for T2DM: ADA/EASD 2018 Recommendations

29. Patient Selection With Cardiorenal Protective Glucose-Lowering Agents

30. Decision Cycle for Patient-Centered Glycemic Management in Type 2 Diabetes

31. Summary and Conclusions

32. Abbreviations

33. Abbreviations (cont)